Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AGTC
- CUSIP: N/A
- Web: www.agtc.com
Capitalization:- Market Cap: $66.02 million
- Outstanding Shares: 18,087,000
Average Prices:- 50 Day Moving Avg: $4.62
- 200 Day Moving Avg: $5.49
- 52 Week Range: $3.50 - $10.85
P/E:- Trailing P/E Ratio: 182.50
- Foreward P/E Ratio: -2.11
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $39.47 million
- Price / Sales: 1.67
- Book Value: $6.38 per share
- Price / Book: 0.57
Profitability:- EBIDTA: $2.81 million
- Net Margins: 4.28%
- Return on Equity: 1.45%
- Return on Assets: 1.05%
Debt:- Current Ratio: 4.63%
- Quick Ratio: 4.63%
Misc:- Average Volume: 217,512 shs.
- Beta: 1.68
- Short Ratio: 1.72
Frequently Asked Questions for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
What is Applied Genetic Technologies Corporation's stock symbol?
Applied Genetic Technologies Corporation trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies Corporation's earnings last quarter?
Applied Genetic Technologies Corporation (NASDAQ:AGTC) announced its earnings results on Wednesday, September, 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.40. The company earned $8.30 million during the quarter, compared to analysts' expectations of $12.39 million. Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The company's revenue for the quarter was down 31.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.15 earnings per share. View Applied Genetic Technologies Corporation's Earnings History.
When will Applied Genetic Technologies Corporation make its next earnings announcement?
Where is Applied Genetic Technologies Corporation's stock going? Where will Applied Genetic Technologies Corporation's stock price be in 2017?
8 brokers have issued 12-month target prices for Applied Genetic Technologies Corporation's shares. Their predictions range from $7.00 to $16.00. On average, they anticipate Applied Genetic Technologies Corporation's stock price to reach $11.63 in the next year. View Analyst Ratings for Applied Genetic Technologies Corporation.
What are analysts saying about Applied Genetic Technologies Corporation stock?
Here are some recent quotes from research analysts about Applied Genetic Technologies Corporation stock:
- 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/25/2017)
- 2. Rodman & Renshaw analysts commented, "A leader in AAV development; first-in-man data soon and critical to investment case. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. We believe that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked. The company is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.Plenty of cash to fund development. We believe the preclinical data in hand support our projected outcome for positive results from the ongoing clinical programs. We are quickly approaching critical first-in-man data in mid-2017 from the company's lead program in XLRS and initial clinical data from the ACHM program by year-end 2017. We believe these data should help correct the valuation disconnect we call to investors' attention where the stock is trading below the company's cash balance, primarily due to the early stage nature of the platform. Additionally, the company has approximately two years of cash on hand to deliver to our development projections; furthermore, the trajectory should create inflection points that include the clinical data points mentioned as well as advancing more products into development." (3/15/2017)
Who are some of Applied Genetic Technologies Corporation's key competitors?
Some companies that are related to Applied Genetic Technologies Corporation include Axsome Therapeutics (AXSM), Cidara Therapeutics (CDTX), Synthetic Biologics (SYN), MaxCyte (MXCT), Sorrento Therapeutics (SRNE), Verona Pharma Plc (VRP), Intec Pharma (NTEC), Summit Therapeutics PLC (SUMM), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), MEI Pharma (MEIP), Otonomy (OTIC), Ophthotech Corporation (OPHT), Akari Therapeutics PLC (AKTX), Dicerna Pharmaceuticals (DRNA), Versartis (VSAR), Zafgen (ZFGN) and Affimed N.V. (AFMD).
Who are Applied Genetic Technologies Corporation's key executives?
Applied Genetic Technologies Corporation's management team includes the folowing people:
- Scott Koenig M.D., Ph.D., Chairman of the Board
- Susan B. Washer, President, Chief Executive Officer, Director
- William A. Sullivan, Chief Financial Officer
- Jeffrey D. Chulay M.D., Senior Vice President, Chief Medical Officer
- Mark Shearman Ph.D., Chief Scientific Officer
- Stephen B. Potter, Vice president and chief business officer
- Andrew D. Ashe, General Counsel
- Michael H. Goldstein, Chief Medical Officer
- David R. Guyer M.D., Director
- Ivana Magovcevic-Liebisch Ph.D. J.D., Director
Who owns Applied Genetic Technologies Corporation stock?
Applied Genetic Technologies Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include InterWest Venture Management Co (8.05%), Numeric Investors LLC (4.32%), Acadian Asset Management LLC (3.92%), FMR LLC (3.70%), Vanguard Group Inc. (2.75%) and AJO LP (2.61%). Company insiders that own Applied Genetic Technologies Corporation stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies Corporation.
Who sold Applied Genetic Technologies Corporation stock? Who is selling Applied Genetic Technologies Corporation stock?
Applied Genetic Technologies Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Northern Trust Corp, Vanguard Group Inc., Bank of New York Mellon Corp, Acadian Asset Management LLC, GSA Capital Partners LLP, Granite Investment Partners LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Applied Genetic Technologies Corporation.
Who bought Applied Genetic Technologies Corporation stock? Who is buying Applied Genetic Technologies Corporation stock?
Applied Genetic Technologies Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Numeric Investors LLC, Goldman Sachs Group Inc., Steinberg Global Asset Management, Dimensional Fund Advisors LP, Ativo Capital Management LLC, LMR Partners LLP and Virtu KCG Holdings LLC. Company insiders that have bought Applied Genetic Technologies Corporation stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies Corporation.
How do I buy Applied Genetic Technologies Corporation stock?
Shares of Applied Genetic Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies Corporation's stock price today?
One share of Applied Genetic Technologies Corporation stock can currently be purchased for approximately $3.65.
MarketBeat Community Rating for Applied Genetic Technologies Corporation (NASDAQ AGTC)MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Applied Genetic Technologies Corporation (NASDAQ:AGTC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $11.63 (218.49% upside) |
Analysts' Ratings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | HC Wainwright | Reiterated Rating | Buy | $16.00 -> $8.00 | High |  |
| 9/14/2017 | Cantor Fitzgerald | Lower Price Target | Neutral | $15.00 -> $9.00 | High | |
| 9/14/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $14.00 -> $7.00 | High | |
| 9/14/2017 | Stifel Nicolaus | Lower Price Target | Buy -> Buy | $15.00 -> $12.00 | High | |
| 3/15/2017 | Rodman & Renshaw | Initiated Coverage | Buy -> Buy | $16.00 | High | |
| 2/9/2017 | Wedbush | Reiterated Rating | Outperform | $15.00 | N/A | |
| 11/9/2016 | Roth Capital | Upgrade | Neutral -> Buy | $12.00 -> $15.00 | N/A | |
| 9/26/2016 | Janney Montgomery Scott | Upgrade | Sell -> Neutral | $11.00 | N/A | |
| 9/13/2016 | Wells Fargo & Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 1/10/2016 | Chardan Capital | Reiterated Rating | Buy | $25.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)Earnings History by Quarter for Applied Genetic Technologies Corporation (NASDAQ AGTC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2017 | | | | | | | | |
| 9/13/2017 | Q4 2017 | $0.22 | ($0.18) | $12.39 million | $8.30 million | View | N/A | |
| 5/10/2017 | Q3 2017 | ($0.01) | ($0.05) | $10.39 million | $8.39 million | View | N/A | |
| 2/8/2017 | Q217 | $0.02 | $0.11 | $11.10 million | $10.90 million | View | Listen | |
| 11/8/2016 | Q117 | ($0.10) | $0.20 | $10.21 million | $11.80 million | View | Listen | |
| 9/12/2016 | Q416 | $0.07 | $0.15 | $13.10 million | $12.10 million | View | Listen | |
| 5/9/2016 | Q3 | $0.05 | $0.11 | $12.98 million | $12.00 million | View | N/A | |
| 2/8/2016 | Q216 | ($0.19) | $0.17 | $8.76 million | $12.20 million | View | N/A | |
| 11/5/2015 | Q1 | ($0.20) | ($0.53) | $5.91 million | $11.06 million | View | N/A | |
| 9/10/2015 | Q415 | ($0.41) | ($0.48) | $0.63 million | $0.71 million | View | N/A | |
| 5/11/2015 | Q315 | ($0.33) | ($0.38) | $0.59 million | $0.28 million | View | N/A | |
| 2/11/2015 | Q215 | ($0.39) | ($0.28) | $0.45 million | $0.65 million | View | N/A | |
| 11/12/2014 | Q115 | ($0.29) | ($0.34) | $258.00 million | $705.00 million | View | N/A | |
| 9/26/2014 | Q414 | ($0.29) | ($0.32) | $0.23 million | $0.12 million | View | N/A | |
| 5/14/2014 | Q114 | ($0.37) | ($25.45) | $0.15 million | $0.23 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)2017 EPS Consensus Estimate: ($0.36)
2018 EPS Consensus Estimate: ($1.23)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.45) | $0.09 | ($0.18) |
| Q2 2017 | 2 | ($0.04) | ($0.02) | ($0.03) |
| Q3 2017 | 2 | ($0.14) | $0.04 | ($0.05) |
| Q4 2017 | 2 | ($0.16) | ($0.04) | ($0.10) |
| Q1 2018 | 1 | ($0.18) | ($0.18) | ($0.18) |
| Q2 2018 | 1 | $0.01 | $0.01 | $0.01 |
| Q3 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q4 2018 | 1 | ($0.71) | ($0.71) | ($0.71) |
(Data provided by Zacks Investment Research)
Dividend History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.75%
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/16/2016 | Ivana Magovcevic | Director | Buy | 3,000 | $9.63 | $28,890.00 | |
| 11/1/2016 | Jeffrey D Chulay | VP | Sell | 1,000 | $7.05 | $7,050.00 | |
| 9/22/2016 | Mark S Shearman | Insider | Buy | 3,000 | $8.87 | $26,610.00 | |
| 9/20/2016 | Stephen W Potter | Insider | Buy | 1,400 | $8.89 | $12,446.00 | |
| 9/19/2016 | Lawrence E Bullock | CFO | Buy | 10,000 | $8.75 | $87,500.00 | |
| 2/23/2015 | Plc Glaxosmithkline | Major Shareholder | Sell | 503,150 | $22.00 | $11,069,300.00 | |
| 1/23/2015 | Daniel L Menichella | VP | Sell | 1,996 | $24.90 | $49,700.40 | |
| 12/22/2014 | Daniel L Menichella | VP | Sell | 9,000 | $20.83 | $187,470.00 | |
| 4/1/2014 | Interwest Partners Viii Lp | Major Shareholder | Buy | 75,376 | $12.00 | $904,512.00 | |
| 4/1/2014 | Jill Carroll | Director | Buy | 103,762 | $12.00 | $1,245,144.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Latest Headlines for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
| Source: |
|
| Date | Headline |
|---|
 | AGTC to Present at Upcoming Conferences
finance.yahoo.com - September 20 at 3:30 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : September 19, 2017
finance.yahoo.com - September 19 at 8:43 PM |
| Applied Genetic Technologies Corporation (AGTC)
finance.yahoo.com - September 18 at 9:06 PM |
| Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 4:04 PM |
 | Q1 2018 EPS Estimates for Applied Genetic Technologies Corporation (AGTC) Cut by Analyst
www.americanbankingnews.com - September 18 at 4:30 AM |
| Applied Genetic Technologies Corporation (AGTC) Expected to Post Quarterly Sales of $7.83 Million
www.americanbankingnews.com - September 18 at 1:40 AM |
| Applied Genetic Technologies Corporation (AGTC) PT Lowered to $9.00
www.americanbankingnews.com - September 16 at 9:04 PM |
| ValuEngine Lowers Applied Genetic Technologies Corporation (AGTC) to Sell
www.americanbankingnews.com - September 16 at 7:44 PM |
| Wedbush Comments on Applied Genetic Technologies Corporation's FY2022 Earnings (AGTC)
www.americanbankingnews.com - September 15 at 4:52 PM |
| HC Wainwright Reiterates Buy Rating for Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - September 14 at 12:28 PM |
| BMO Capital Markets Reiterates Outperform Rating for Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - September 14 at 9:35 AM |
| Applied Genetic Technologies Corporation (AGTC) PT Lowered to $12.00
www.americanbankingnews.com - September 14 at 9:34 AM |
 | AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30,
www.nasdaq.com - September 13 at 9:45 PM |
 | Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - September 13 at 9:45 PM |
 | Applied Genetic Technologies Corp. (AGTC) PT Lowered to $12 at Stifel
www.streetinsider.com - September 13 at 9:45 PM |
| Edited Transcript of AGTC earnings conference call or presentation 13-Sep-17 12:00pm GMT
finance.yahoo.com - September 13 at 9:45 PM |
| AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017
finance.yahoo.com - September 13 at 4:43 PM |
| Applied Genetic Technologies posts 4Q loss
finance.yahoo.com - September 13 at 4:43 PM |
| Applied Genetic Technologies Corp (AGTC) Posts Quarterly Earnings Results, Misses Estimates By $0.32 EPS
www.americanbankingnews.com - September 13 at 1:00 PM |
| Applied Genetic Technologies Corp (AGTC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 9:30 AM |
 | BRIEF-AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer
www.reuters.com - September 6 at 8:35 PM |
| Applied Genetic Technologies Corporation (AGTC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - September 6 at 2:12 AM |
| AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer
finance.yahoo.com - September 5 at 9:39 PM |
| AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017
finance.yahoo.com - August 31 at 3:29 PM |
| Applied Genetic Technologies Corporation (AGTC) Expected to Announce Quarterly Sales of $13.43 Million
www.americanbankingnews.com - August 31 at 9:38 AM |
| Applied Genetic Technologies Corporation (AGTC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 19 at 9:12 AM |
| Applied Genetic Technologies Corporation (AGTC) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 17 at 10:05 PM |
| BRIEF-Applied Genetic Technologies partners with the Foundation Fighting Blindness
www.reuters.com - August 15 at 4:40 PM |
| AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
finance.yahoo.com - August 15 at 4:40 PM |
| Analysts Expect Applied Genetic Technologies Corporation (NASDAQ:AGTC) to Post $0.11 Earnings Per Share
www.americanbankingnews.com - August 10 at 11:10 PM |
| AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
finance.yahoo.com - August 10 at 5:03 PM |
| Applied Genetic Technologies Corporation (NASDAQ:AGTC) Given a $16.00 Price Target at HC Wainwright
www.americanbankingnews.com - August 10 at 3:03 PM |
 | AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
feeds.benzinga.com - August 8 at 8:07 AM |
| AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
finance.yahoo.com - August 3 at 4:43 PM |
| AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
finance.yahoo.com - August 3 at 4:43 PM |
| BRIEF-AGTC appoints William Sullivan as chief financial officer
www.reuters.com - August 2 at 8:33 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : July 31, 2017
finance.yahoo.com - July 31 at 8:48 PM |
| Applied Genetic Technologies Corp (AGTC) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - July 25 at 11:28 PM |
| Applied Genetic Technologies Corp (AGTC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 25 at 11:28 AM |
| Brokerages Anticipate Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $12.36 Million
www.americanbankingnews.com - July 23 at 8:30 AM |
| Applied Genetic Technologies Corporation (AGTC) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - July 21 at 6:28 PM |
| Comparing Gilead Sciences (GILD) & Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - July 16 at 7:46 AM |
| Applied Genetic Technologies Corporation (NASDAQ:AGTC) Sees Large Drop in Short Interest
www.americanbankingnews.com - July 16 at 7:06 AM |
| ETFs with exposure to Applied Genetic Technologies Corp. : July 13, 2017
finance.yahoo.com - July 13 at 4:18 PM |
| Applied Genetic Technologies Corporation (NASDAQ:AGTC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : July 3, 2017
finance.yahoo.com - July 3 at 3:33 PM |
| Applied Genetic Technologies Corporation (AGTC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 11:04 AM |
| Applied Genetic Technologies Corporation (AGTC) Expected to Announce Quarterly Sales of $12.36 Million
www.americanbankingnews.com - June 29 at 11:04 AM |
| Applied Genetic Technologies Corporation (AGTC) Expected to Post Earnings of $0.11 Per Share
www.americanbankingnews.com - June 27 at 2:20 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : June 19, 2017
finance.yahoo.com - June 19 at 3:26 PM |
Applied Genetic Technologies Corporation (AGTC) Chart for Sunday, September, 24, 2017
